ADMA Biologics, Inc.
ADMA
$6.55
$0.111.71%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 73.90M | 67.27M | 60.12M | 56.91M | 49.98M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 73.90M | 67.27M | 60.12M | 56.91M | 49.98M |
| Cost of Revenue | 42.82M | 42.62M | 41.33M | 40.40M | 35.80M |
| Gross Profit | 31.09M | 24.65M | 18.79M | 16.51M | 14.18M |
| SG&A Expenses | 16.22M | 14.49M | 14.88M | 16.29M | 18.98M |
| Depreciation & Amortization | 187.50K | 178.80K | 178.80K | 178.80K | 178.50K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.67M | 57.89M | 57.80M | 57.73M | 56.04M |
| Operating Income | 14.23M | 9.39M | 2.33M | -813.30K | -6.06M |
| Income Before Tax | -17.64M | 2.57M | -6.37M | -6.79M | -12.23M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.64M | 2.57M | -6.37M | -6.79M | -12.23M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.64M | 2.57M | -6.37M | -6.79M | -12.23M |
| EBIT | 14.23M | 9.39M | 2.33M | -813.30K | -6.06M |
| EBITDA | 16.33M | 11.48M | 4.42M | 1.22M | -4.12M |
| EPS Basic | -0.08 | 0.01 | -0.03 | -0.03 | -0.06 |
| Normalized Basic EPS | 0.02 | 0.01 | -0.01 | -0.02 | -0.04 |
| EPS Diluted | -0.08 | 0.01 | -0.03 | -0.03 | -0.06 |
| Normalized Diluted EPS | 0.02 | 0.01 | -0.01 | -0.02 | -0.04 |
| Average Basic Shares Outstanding | 225.97M | 225.28M | 222.68M | 221.92M | 202.83M |
| Average Diluted Shares Outstanding | 225.97M | 233.76M | 222.68M | 221.92M | 202.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
